Cargando…

Mastocytosis: One Word for Different Diseases

Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Criscuolo, Marianna, Fianchi, Luana, Maraglino, Alessio M. E., Pagano, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360005/
https://www.ncbi.nlm.nih.gov/pubmed/32700030
http://dx.doi.org/10.1007/s40487-018-0086-2
_version_ 1783559151358574592
author Criscuolo, Marianna
Fianchi, Luana
Maraglino, Alessio M. E.
Pagano, Livio
author_facet Criscuolo, Marianna
Fianchi, Luana
Maraglino, Alessio M. E.
Pagano, Livio
author_sort Criscuolo, Marianna
collection PubMed
description Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia.
format Online
Article
Text
id pubmed-7360005
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-73600052020-07-20 Mastocytosis: One Word for Different Diseases Criscuolo, Marianna Fianchi, Luana Maraglino, Alessio M. E. Pagano, Livio Oncol Ther Review Mastocytosis is a neoplastic disease originating from tissue infiltration by transformed mast cells. The diagnosis requires a high grade of suspicion due to the large variety of presenting symptoms. The World Health Organization classification recognizes localized (cutaneous) and systemic forms of the disease, with these forms showing different degrees of aggressiveness. Mastocytosis is often a multiorgan disease, and its correct management requires a multidisciplinary team of experienced consultants to provide overall patient care. Bone marrow evaluation by molecular analyses, skeleton X-ray and abdominal scan together with allergologic and dermatologic evaluation constitute the essential diagnostic work-up for adult patients with mastocytosis. As clinical situations vary, treatment options range from the use of drugs to treat the symptoms, such as anti-H1 receptors and steroids, to UV irradiation, which is overwhelmingly used in patients with cutaneous mastocytosis (CM) or indolent systemic mastocytosis, to cytoreductive treatment to control life-threatening symptoms or organ damage in the more aggressive forms of the disease. Prognosis also widely differs among patients diagnosed with mastocytosis, with the spectrum ranging from an almost normal life expectancy for those with CM and to less than 1-year median overall survival for those with mast cell leukemia. Springer Healthcare 2018-10-29 /pmc/articles/PMC7360005/ /pubmed/32700030 http://dx.doi.org/10.1007/s40487-018-0086-2 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Criscuolo, Marianna
Fianchi, Luana
Maraglino, Alessio M. E.
Pagano, Livio
Mastocytosis: One Word for Different Diseases
title Mastocytosis: One Word for Different Diseases
title_full Mastocytosis: One Word for Different Diseases
title_fullStr Mastocytosis: One Word for Different Diseases
title_full_unstemmed Mastocytosis: One Word for Different Diseases
title_short Mastocytosis: One Word for Different Diseases
title_sort mastocytosis: one word for different diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360005/
https://www.ncbi.nlm.nih.gov/pubmed/32700030
http://dx.doi.org/10.1007/s40487-018-0086-2
work_keys_str_mv AT criscuolomarianna mastocytosisonewordfordifferentdiseases
AT fianchiluana mastocytosisonewordfordifferentdiseases
AT maraglinoalessiome mastocytosisonewordfordifferentdiseases
AT paganolivio mastocytosisonewordfordifferentdiseases